MOBILE VIEW  | 

HENNA

Classification   |    Detailed evidence-based information

Therapeutic Toxic Class

    A) Henna is obtained from the leaves of the Lawsonia inermis (Lythraceae).
    B) Black henna (Indigofera argentea) is botanically different from red henna (Lawsonia inermis).
    C) In many parts of the world, henna dye is frequently mixed with paraphenylenediamine to dye nails, skin, and hair. PPD can cause serious adverse reactions.
    1) Refer to "PARAPHENYLENEDIAMINE" management for further information.

Specific Substances

    1) Alcanna
    2) Egyptian Privet
    3) Hennae folium
    4) Henne
    5) Jamaica Mignonette
    6) Lawsonia inermis
    7) Lawsonia alba
    8) Mehndi
    9) Mendee
    10) Mignonette Tree
    11) Reseda
    12) Smooth Lawsonia

Available Forms Sources

    A) FORMS
    1) Henna is available in various types and colors, either as dried leaves or as a powder (Kandil et al, 1996; Zinkham & Oski, 1996).
    B) USES
    1) In the US, henna is used externally as an ingredient in hair dye and skin lotions (Prod Info Henna, 2003; Jellin et al, 2000; Kandil et al, 1996). In Africa, the Middle East and India, it is used to dye (henna tattoos) and decorate the feet and hands for special social events, such as weddings and circumcisions (Bolhaar et al, 2001; Kandil et al, 1996; Zinkham & Oski, 1996).
    2) Henna has also been used to treat gastrointestinal ulcers, amebic dysentery, leprosy , bacterial and fungal skin infections, amenorrhea, dysmenorrhea, ulcers, dysuria, coughs, bronchitis, headache, rheumatism and anemia (Prod Info Henna, 2003; Jellin et al, 2000; Kandil et al, 1996).
    3) In Bedouin tribe (from north-west Kuwait), henna dye (a mixture of pure leaves, water and salt) is applied to the body of newborn babies for its antiseptic effect and to celebrate the arrival of the first-born son (Kandil et al, 1996).
    4) A recent study found that certain plant extracts mixed with henna extract were effective in treating head lice (El-Basheir & Fouad, 2002).

Life Support

    A) This overview assumes that basic life support measures have been instituted.

Clinical Effects

    0.2.1) SUMMARY OF EXPOSURE
    A) USES: In the US, henna is used externally as an ingredient in hair dye and skin lotions. In Africa, the Middle East and India, it is used to dye (henna tattoos) and decorate the feet and hands for special social events, such as weddings and circumcisions. Henna has also been used to treat gastrointestinal ulcers, amebic dysentery, leprosy, bacterial and fungal skin infections, amenorrhea, dysmenorrhea, ulcers, dysuria, coughs, bronchitis, headache, rheumatism and anemia.
    B) PHARMACOLOGY: Henna is obtained from the leaves of the Lawsonia inermis (Lythraceae). Black henna (Indigofera argentea) is botanically different from red henna (Lawsonia inermis). Henna has been reported to possess astringent, diuretic, antitumor, antispasmodic, cardio-inhibitory, hypotensive, anti-infective, and uterine sedative effects. The aqueous extract of henna has been reported to have strong tuberculostatic activity in vitro and in vivo.
    C) EPIDEMIOLOGY: Exposure is common in other countries. Severe toxicity is rare.
    D) WITH POISONING/EXPOSURE
    1) TOXICITY: Although the topical use of henna is generally safe, it can cause contact dermatitis. In glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals, topical henna use has been associated with hemolysis, anemia, reticulocytosis, and indirect hyperbilirubinemia. Allergy to plain henna is rare; however, it has been reported in several patients. Henna is frequently mixed with paraphenylenediamine (PPD) to reduce the cost and drying time. Respiratory distress, angio-edema, and asthma have been reported in individuals exposed to henna and PPD mixtures. Refer to "PARAPHENYLENEDIAMINE" management for further information.
    0.2.20) REPRODUCTIVE
    A) Henna has been used as an abortifacient in African countries.

Laboratory Monitoring

    A) No specific laboratory tests are necessary unless otherwise clinically indicated.
    B) Plasma concentrations are not readily available or clinically useful in the management of acute exposure.
    C) In glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals, topical henna use has been associated with hemolysis, anemia, reticulocytosis, and indirect hyperbilirubinemia. Obtain a CBC with differential, and monitor renal function and liver enzymes in symptomatic patients.
    D) After a significant ingestion of henna and PPD mixture, monitor airway status, and institute continuous monitoring of ECG and pulse oximetry.

Treatment Overview

    0.4.2) ORAL/PARENTERAL EXPOSURE
    A) MANAGEMENT OF MILD TO MODERATE TOXICITY
    1) Treatment is symptomatic and supportive.
    B) MANAGEMENT OF SEVERE TOXICITY
    1) Treatment is symptomatic and supportive. Severe toxicity may occur in glucose-6-phosphate dehydrogenase (G6PD)-deficient patients. Henna is frequently mixed with paraphenylenediamine (PPD) to reduce the cost and drying time. Respiratory distress, angio-edema, and asthma have been reported in individuals exposed to henna and PPD mixtures. Refer to "PARAPHENYLENEDIAMINE" management for further information.
    C) DECONTAMINATION
    1) PREHOSPITAL: Significant toxic effects are unlikely. Gastrointestinal decontamination is generally not needed.
    2) HOSPITAL: Gastrointestinal decontamination is generally unnecessary. Consider activated charcoal only if coingestants with significant toxicity are involved.
    D) AIRWAY MANAGEMENT
    1) Endotracheal intubation and mechanical ventilation may be required in patients with severe allergic reaction or significant respiratory distress (if mixed with PPD).
    E) ANTIDOTE
    1) None
    F) HYPERSENSITIVITY REACTION
    1) MILD/MODERATE: Monitor airway. Administer antihistamines with or without inhaled beta agonists, corticosteroids, or epinephrine. SEVERE: Oxygen, aggressive airway management, antihistamines, epinephrine, corticosteroids, ECG monitoring, and IV fluids.
    G) ENHANCED ELIMINATION
    1) It is unknown if hemodialysis would be effective.
    H) PATIENTS DISPOSITION
    1) HOME CRITERIA: A patient with an inadvertent exposure, that remains asymptomatic can be managed at home.
    2) OBSERVATION CRITERIA: Patients with a deliberate overdose, and those who are symptomatic, need to be monitored until they are clearly improving and clinically stable.
    3) ADMISSION CRITERIA: Patients with severe symptoms despite treatment should be admitted.
    4) CONSULT CRITERIA: Consult a regional poison center or medical toxicologist for assistance in managing patients with severe toxicity or in whom the diagnosis is not clear.
    I) PITFALLS
    1) Failure to obtain adequate history of exposure. When managing a suspected henna exposure, the possibility of multiagent involvement should be considered.
    J) DIFFERENTIAL DIAGNOSIS
    1) Other drugs or chemicals that can cause contact dermatitis.
    0.4.5) DERMAL EXPOSURE
    A) OVERVIEW
    1) DECONTAMINATION: Remove contaminated clothing and jewelry and place them in plastic bags. Wash exposed areas with soap and water for 10 to 15 minutes with gentle sponging to avoid skin breakdown. A physician may need to examine the area if irritation or pain persists (Burgess et al, 1999).

Range Of Toxicity

    A) TOXICITY: Henna powder, 2 grams 3 times daily, administered orally to 4 patients with intestinal moniliasis (Candidiasis) for 1 month, did not cause any adverse effects.

Summary Of Exposure

    A) USES: In the US, henna is used externally as an ingredient in hair dye and skin lotions. In Africa, the Middle East and India, it is used to dye (henna tattoos) and decorate the feet and hands for special social events, such as weddings and circumcisions. Henna has also been used to treat gastrointestinal ulcers, amebic dysentery, leprosy, bacterial and fungal skin infections, amenorrhea, dysmenorrhea, ulcers, dysuria, coughs, bronchitis, headache, rheumatism and anemia.
    B) PHARMACOLOGY: Henna is obtained from the leaves of the Lawsonia inermis (Lythraceae). Black henna (Indigofera argentea) is botanically different from red henna (Lawsonia inermis). Henna has been reported to possess astringent, diuretic, antitumor, antispasmodic, cardio-inhibitory, hypotensive, anti-infective, and uterine sedative effects. The aqueous extract of henna has been reported to have strong tuberculostatic activity in vitro and in vivo.
    C) EPIDEMIOLOGY: Exposure is common in other countries. Severe toxicity is rare.
    D) WITH POISONING/EXPOSURE
    1) TOXICITY: Although the topical use of henna is generally safe, it can cause contact dermatitis. In glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals, topical henna use has been associated with hemolysis, anemia, reticulocytosis, and indirect hyperbilirubinemia. Allergy to plain henna is rare; however, it has been reported in several patients. Henna is frequently mixed with paraphenylenediamine (PPD) to reduce the cost and drying time. Respiratory distress, angio-edema, and asthma have been reported in individuals exposed to henna and PPD mixtures. Refer to "PARAPHENYLENEDIAMINE" management for further information.

Respiratory

    3.6.2) CLINICAL EFFECTS
    A) ASTHMA
    1) WITH POISONING/EXPOSURE
    a) CASE REPORT: Occupational asthma (rhinorrhea, sneezing, wheezing, nasal obstruction and itching, hyposmia (diminished sense of smell), dysphonia, conjunctivitis, and dry cough) has been reported in a 35-year-old woman working in an herbal shop. She reported that her symptoms worsened when she inhaled the powder of black henna (Indigofera argentea), a species of henna that is botanically distinct from the more common red henna (Lawsonia inermis). Specific IgE antibodies and skin prick tests performed with a 1/10 dilution of the black henna powder were positive for black henna (Scibilia et al, 1997).
    B) ACUTE LUNG INJURY
    1) WITH POISONING/EXPOSURE
    a) CASE REPORT: A 40-year-old woman developed pulmonary edema after applying a henna mixture to her feet. The henna mixture was prepared by a neighbor, who refused to give full details of the preparation. To speed up dyeing, a second dye, paraphenylenediamine (PPD) is usually added to henna. Respiratory distress, angioedema, and asthma have been described in individuals exposed to PPD (Abdulla & Davidson, 1996).

Gastrointestinal

    3.8.2) CLINICAL EFFECTS
    A) DRUG-INDUCED GASTROINTESTINAL DISTURBANCE
    1) WITH POISONING/EXPOSURE
    a) Because of the tannin content, henna may cause stomach complaints (Prod Info Henna, 2003).

Hepatic

    3.9.2) CLINICAL EFFECTS
    A) HYPERBILIRUBINEMIA
    1) WITH POISONING/EXPOSURE
    a) Topical use of henna has been associated with indirect hyperbilirubinemia in infants with glucose 6-phosphate dehydrogenase (G6PD) deficiency (Kandil et al, 1996).
    b) CASE REPORT: A 7-day-old boy with glucose 6-phosphate dehydrogenase (G6PD) deficiency developed severe hyperbilirubinemia secondary to hemolysis within 29 hours of henna application for prevention of diaper rash. Following exchange transfusion and phototherapy, he recovered without further sequelae (Katar et al, 2007).

Genitourinary

    3.10.2) CLINICAL EFFECTS
    A) ACUTE RENAL FAILURE SYNDROME
    1) WITH POISONING/EXPOSURE
    a) CASE REPORT: A 27-day-old G6PD-deficient boy developed hemolytic anemia and acute renal failure after topical use of henna to his abdomen, intertriginous region and legs to treat diaper rash. His condition deteriorated and he died approximately 2 days after admission to the hospital (Devecioglu et al, 2001).
    b) Within a few hours of topical application, an allergic reaction in the form of angioneurotic edema (of the face, lips, pharynx, larynx and bronchi) progressing to acute renal failure and ultimately death due to renal tubular necrosis, may occur (Oztass et al, 2001; Rubegni et al, 2000).
    c) CASE REPORT: A 32-year-old man presented with a 3-day history of feeling unwell, anorexia, fatigue, and abdominal bloating after ingesting a large amount of boiled henna containing PPD. He also had yellowish discoloration of the sclera and dark-colored urine. Laboratory analysis revealed a reduced hemoglobin (8.8 g/dL), and elevated serum creatinine (more than double). Initially, his renal function and hemolysis deteriorated despite supportive care. However, his condition improved following transfusion with packed red blood cells and hemodialysis. He was discharged on day 13 (Qurashi et al, 2013).
    3.10.3) ANIMAL EFFECTS
    A) ANIMAL STUDIES
    1) RENAL TUBULAR NECROSIS
    a) In animals, lawsone (2-hydroxy-1,4-naphthoquinone) has been reported to cause severe hemolytic anemia and renal tubular necrosis (Devecioglu et al, 2001).

Hematologic

    3.13.2) CLINICAL EFFECTS
    A) HEMOLYSIS
    1) WITH POISONING/EXPOSURE
    a) CASE REPORT: A 32-year-old man presented with a 3-day history of feeling unwell, anorexia, fatigue, and abdominal bloating after ingesting a large amount of boiled henna containing PPD. He also had yellowish discoloration of the sclera and dark-colored urine. Laboratory analysis revealed a reduced hemoglobin (8.8 g/dL), and elevated serum creatinine (more than double). Initially, his renal function and hemolysis deteriorated despite supportive care. However, his condition improved following transfusion with packed red blood cells and hemodialysis. He was discharged on day 13 (Qurashi et al, 2013).
    b) CASE SERIES: In 15 glucose-6-phosphate dehydrogenase (G6PD)-deficient male newborns, topical henna use was associated with hemolysis, anemia, reticulocytosis, and indirect hyperbilirubinemia. The hemolytic episode occurred within a few hours to 3 days after administration of the henna and reticulocytosis began at about 5 days (Kandil et al, 1996).
    c) CASE SERIES: Four glucose-6-phosphate dehydrogenase deficient children developed hemolytic crisis after topical application of henna; a female neonate (hemoglobin 50 g/L, serum bilirubin 700 mcmol/L) and two preschool children (hemoglobin 40 and 41 g/L, respectively) recovered after exchange transfusion; one male infant (hemoglobin 28 g/L) died despite transfusion (Raupp et al, 2001).
    d) In vitro studies indicate that lawsone, a chemical constituent of henna, is capable of inducing oxidative injury to G6PD-normal red cells. Since 100 grams of henna is required to dye the palms and soles of an adult, and assuming that the surface area of the infant is approximately 1/10 that of an adult, then an infant, with dyed palms or soles, would probably be exposed to 10 grams of henna (1 gram of lawsone). Therefore, the percutaneous absorption of henna may induce oxidative injury to neonatal red cells (Zinkham & Oski, 1996).
    e) CASE REPORT: A 27-day-old G6PD-deficient boy developed hemolytic anemia and acute renal failure after topical use of henna to his abdomen, intertriginous region and legs to treat diaper rash. His condition deteriorated and he died approximately 2 days after admission to the hospital (Devecioglu et al, 2001).
    f) CASE SERIES: Two glucose-6-phosphate dehydrogenase (G6PD) enzyme deficient siblings (an 11-year-old boy and a 7-year-old girl) developed hemolytic anemia after the topical application of henna to their whole body to treat skin lesions (ichthyosis vulgaris). Although the 11-year-old boy recovered completely and was discharged after 4 days, his sister's condition deteriorated despite transfusion and she died approximately 2 days after admission (Kok et al, 2004).
    3.13.3) ANIMAL EFFECTS
    A) ANIMAL STUDIES
    1) HEMOLYTIC ANEMIA
    a) In animals, lawsone (2-hydroxy-1,4-naphthoquinone) has been reported to cause severe hemolytic anemia and renal tubular necrosis (Devecioglu et al, 2001). This finding has also been suggested following in vitro experiments (Zinkham & Oski, 1996).

Dermatologic

    3.14.2) CLINICAL EFFECTS
    A) DISORDER OF SKIN
    1) WITH POISONING/EXPOSURE
    a) Topical use of henna and more commonly paraphenylenediamine can cause contact and allergic dermatitis (Nawaf et al, 2003; Chung et al, 2002; Chung et al, 2001; Jellin et al, 2000; Lestringant et al, 1999; Duke, 1985).
    b) CASE REPORT: A 38-year-old man developed a patterned lichenoid reaction (a red palpable skin reaction, with the tattooed area raised 0.5 cm above the surrounding skin) on the neck 20 days after receiving a henna non-permanent tribal tattoo during a trip to east Africa (Zanzibar). A biopsy revealed a typical lichenoid dermal infiltrate with erosion of the basal layer of the epidermis (Rubegni et al, 2000).
    c) CASE SERIES: Lichenoid reactions in 4 patients with temporary tattoos, from black henna, were found to have high concentrations of para-phenylenediamine (detected by mass spectrometry) in skin biopsy samples (Chung et al, 2002).
    d) CASE REPORT: A 17-year-old female developed acute contact dermatitis, consisting of blisters, within 72 hours of applying temporary henna tattoos to her hands. Subsequent skin testing revealed that her allergy was to para-phenylenediamine, not natural henna (Nawaf et al, 2003).

Immunologic

    3.19.2) CLINICAL EFFECTS
    A) ACUTE ALLERGIC REACTION
    1) WITH POISONING/EXPOSURE
    a) Allergy to plain henna is rare; however, it has been reported in several patients. Allergy to henna is usually related to the coloring material itself, a hydroxynaphthoquinone, or the additives such as PPD and a scented oil. There are many case reports in the medical literature describing confirmed allergic reactions to PPD (Nawaf et al, 2003; Wolf et al, 2003; Chung et al, 2002; Chung et al, 2001; Rubegni et al, 2000; Lestringant et al, 1999; Majoie & Bruynzeel, 1996).
    b) CASE REPORT: A 10-year-old girl developed allergic contact dermatitis (type IV delayed hypersensitivity reaction) after receiving a henna tattoo to her left arm while in India. A well-demarcated, indurated, erythematous papular eruption confined to the area of the henna tattoo was observed. Patch testing revealed a strong positive reaction to PPD, with additional reactions to a number of substances found in hair products (Bowling & Groves, 2002).
    c) An immediate-type hypersensitivity (urticaria, rhinitis, bronchial asthma, sneezing, conjunctivitis, dry cough, and severe dyspnea) to henna was reported in 2 hairdressers (Bolhaar et al, 2001; Majoie & Bruynzeel, 1996). It was reported that the hypersensitivity was due to induction of specific IgE antibodies to henna (Bolhaar et al, 2001).
    d) CASE REPORT: A 38-year-old teacher developed severe angioedema (eyelids, face, forehead, scalp, and tongue) within 4 hours of using a commercial hair dye product containing henna (Oztass et al, 2001).
    e) CASE REPORT: Fatal anaphylaxis developed in a 15-year-old girl after ingesting an unknown amount of henna in a suicide attempt. Autopsy revealed laryngeal edema and pulmonary congestion (Kok et al, 2005).

Reproductive

    3.20.1) SUMMARY
    A) Henna has been used as an abortifacient in African countries.
    3.20.3) EFFECTS IN PREGNANCY
    A) ANIMAL STUDIES
    1) Henna has been used as an abortifacient in African countries (Prod Info Henna, 2003; Jellin et al, 2000).

Monitoring Parameters Levels

    4.1.1) SUMMARY
    A) No specific laboratory tests are necessary unless otherwise clinically indicated.
    B) Plasma concentrations are not readily available or clinically useful in the management of acute exposure.
    C) In glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals, topical henna use has been associated with hemolysis, anemia, reticulocytosis, and indirect hyperbilirubinemia. Obtain a CBC with differential, and monitor renal function and liver enzymes in symptomatic patients.
    D) After a significant ingestion of henna and PPD mixture, monitor airway status, and institute continuous monitoring of ECG and pulse oximetry.
    4.1.2) SERUM/BLOOD
    A) BLOOD/SERUM CHEMISTRY
    1) In glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals, topical henna use has been associated with hemolysis, anemia, reticulocytosis, and indirect hyperbilirubinemia (Kandil et al, 1996). Obtain a CBC with differential, and monitor renal function and liver enzymes in symptomatic patients.
    2) Henna is frequently mixed with paraphenylenediamine (PPD) to reduce the cost and drying time. Respiratory distress, angioedema, and asthma have been reported in individuals exposed to henna and PPD mixtures (Oztass et al, 2001; Lestringant et al, 1999; Zinkham & Oski, 1996; Abdulla & Davidson, 1996; Kandil et al, 1996). Monitor airway status, institute continuous monitoring of ECG and oxygenation (pulse oximetry) after significant ingestion.
    a) Refer to "PARAPHENYLENEDIAMINE" management for further information.

Life Support

    A) Support respiratory and cardiovascular function.

Patient Disposition

    6.3.1) DISPOSITION/ORAL EXPOSURE
    6.3.1.1) ADMISSION CRITERIA/ORAL
    A) Patients with severe symptoms despite treatment should be admitted.
    6.3.1.2) HOME CRITERIA/ORAL
    A) A patient with an inadvertent exposure, that remains asymptomatic can be managed at home.
    6.3.1.3) CONSULT CRITERIA/ORAL
    A) Consult a regional poison center or medical toxicologist for assistance in managing patients with severe toxicity or in whom the diagnosis is not clear.
    6.3.1.5) OBSERVATION CRITERIA/ORAL
    A) Patients with a deliberate overdose, and those who are symptomatic, need to be monitored until they are clearly improving and clinically stable.

Monitoring

    A) No specific laboratory tests are necessary unless otherwise clinically indicated.
    B) Plasma concentrations are not readily available or clinically useful in the management of acute exposure.
    C) In glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals, topical henna use has been associated with hemolysis, anemia, reticulocytosis, and indirect hyperbilirubinemia. Obtain a CBC with differential, and monitor renal function and liver enzymes in symptomatic patients.
    D) After a significant ingestion of henna and PPD mixture, monitor airway status, and institute continuous monitoring of ECG and pulse oximetry.

Oral Exposure

    6.5.1) PREVENTION OF ABSORPTION/PREHOSPITAL
    A) Significant toxic effects are unlikely. Gastrointestinal decontamination is generally not needed.
    6.5.2) PREVENTION OF ABSORPTION
    A) Gastrointestinal decontamination is generally unnecessary. Consider activated charcoal only if coingestants with significant toxicity are involved.
    B) ACTIVATED CHARCOAL
    1) CHARCOAL ADMINISTRATION
    a) Consider administration of activated charcoal after a potentially toxic ingestion (Chyka et al, 2005). Administer charcoal as an aqueous slurry; most effective when administered within one hour of ingestion.
    2) CHARCOAL DOSE
    a) Use a minimum of 240 milliliters of water per 30 grams charcoal (FDA, 1985). Optimum dose not established; usual dose is 25 to 100 grams in adults and adolescents; 25 to 50 grams in children aged 1 to 12 years (or 0.5 to 1 gram/kilogram body weight) ; and 0.5 to 1 gram/kilogram in infants up to 1 year old (Chyka et al, 2005).
    1) Routine use of a cathartic with activated charcoal is NOT recommended as there is no evidence that cathartics reduce drug absorption and cathartics are known to cause adverse effects such as nausea, vomiting, abdominal cramps, electrolyte imbalances and occasionally hypotension (None Listed, 2004).
    b) ADVERSE EFFECTS/CONTRAINDICATIONS
    1) Complications: emesis, aspiration (Chyka et al, 2005). Aspiration may be complicated by acute respiratory failure, ARDS, bronchiolitis obliterans or chronic lung disease (Golej et al, 2001; Graff et al, 2002; Pollack et al, 1981; Harris & Filandrinos, 1993; Elliot et al, 1989; Rau et al, 1988; Golej et al, 2001; Graff et al, 2002). Refer to the ACTIVATED CHARCOAL/TREATMENT management for further information.
    2) Contraindications: unprotected airway (increases risk/severity of aspiration) , nonfunctioning gastrointestinal tract, uncontrolled vomiting, and ingestion of most hydrocarbons (Chyka et al, 2005).
    6.5.3) TREATMENT
    A) SUPPORT
    1) MANAGEMENT OF MILD TO MODERATE TOXICITY
    a) Treatment is symptomatic and supportive.
    2) MANAGEMENT OF SEVERE TOXICITY
    a) Treatment is symptomatic and supportive. Severe toxicity may occur in glucose-6-phosphate dehydrogenase (G6PD)-deficient patients.
    b) Henna is frequently mixed with paraphenylenediamine (PPD) to reduce the cost and drying time. Respiratory distress, angioedema, and asthma have been reported in individuals exposed to henna and PPD mixtures (Oztass et al, 2001; Lestringant et al, 1999; Zinkham & Oski, 1996; Abdulla & Davidson, 1996; Kandil et al, 1996).
    c) Refer to "PARAPHENYLENEDIAMINE" management for further information.
    B) MONITORING OF PATIENT
    1) No specific laboratory tests are necessary unless otherwise clinically indicated.
    2) Plasma concentrations are not readily available or clinically useful in the management of acute exposure.
    3) In glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals, topical henna use has been associated with hemolysis, anemia, reticulocytosis, and indirect hyperbilirubinemia. Obtain a CBC with differential, and monitor renal function and liver enzymes in symptomatic patients.
    4) After a significant ingestion of henna and PPD mixture, monitor airway status, and institute continuous monitoring of ECG and pulse oximetry.

Dermal Exposure

    6.9.1) DECONTAMINATION
    A) DERMAL DECONTAMINATION
    1) DECONTAMINATION: Remove contaminated clothing and wash exposed area thoroughly with soap and water for 10 to 15 minutes. A physician may need to examine the area if irritation or pain persists (Burgess et al, 1999).
    6.9.2) TREATMENT
    A) CONTACT DERMATITIS
    1) Topical, oral, or parenteral corticosteroids and oral or parenteral antihistamines may be needed to treat contact dermatitis and allergic reactions (route of drug administered to be determined by the nature and severity of the reaction and after physician evaluation).
    B) Treatment should include recommendations listed in the ORAL EXPOSURE section when appropriate.

Summary

    A) TOXICITY: Henna powder, 2 grams 3 times daily, administered orally to 4 patients with intestinal moniliasis (Candidiasis) for 1 month, did not cause any adverse effects.

Maximum Tolerated Exposure

    A) GENERAL
    1) Since 100 grams of henna is required to dye the palms and soles of an adult, and assuming that the surface area of the infant is approximately 1/10 that of an adult, then an infant, with dyed palms or soles, would probably be exposed to 10 grams of henna (1 gram of lawsone) (Zinkham & Oski, 1996).
    2) Henna powder, 2 grams three times daily, administered orally to 4 patients with intestinal moniliasis for 1 month, did not cause any adverse effects (Zinkham & Oski, 1996).

Pharmacologic Mechanism

    A) Henna has been reported to possess astringent and diuretic, antitumor, antispasmodic, cardio-inhibitory, hypotensive, and uterine sedative effects (Prod Info Henna, 2003; Jellin et al, 2000; Duke, 1985).
    B) Henna has been used to treat bacterial and fungal skin infections. The aqueous extract of henna has been reported to have strong tuberculostatic activity in vitro and in vivo (Kandil et al, 1996).

General Bibliography

    1) Abdulla KA & Davidson NM: A woman who collapsed after painting her soles. Lancet 1996; 348(9028):658-.
    2) Bolhaar STHP, Mulder M, & van Ginkel CJW: IgE-mediated allergy to henna. Allergy 2001; 56(3):248.
    3) Bowling JCR & Groves R: Clinical picture. An unexpected tattoo. Lancet 2002; 359(9307):649.
    4) Burgess JL, Kirk M, Borron SW, et al: Emergency department hazardous materials protocol for contaminated patients. Ann Emerg Med 1999; 34(2):205-212.
    5) Chung WH, Chang YC, Yang LJ, et al: Clinicopathologic features of skin reactions to temporary tattoos and analysis of possible causes. Arch Dermatol 2002; 138:88-91.
    6) Chung WH, Wang CM, & Hong HS: Report. Allergic contact dermatitis to temporary tattoos with positive para-phenylenediamine reactions: report of four cases. Int J Dermatol 2001; 40:754-756.
    7) Chyka PA, Seger D, Krenzelok EP, et al: Position paper: Single-dose activated charcoal. Clin Toxicol (Phila) 2005; 43(2):61-87.
    8) Devecioglu C, Katar S, & Dogru O: Henna-induced hemolytic anemia and acute renal failure. Turk J Pediatr 2001; 43:65-66.
    9) Duke JA: CRC Handbook of Medicinal Herbs, CRC Press, Inc, Boca Raton, FL, 1985.
    10) El-Basheir ZM & Fouad MA: A preliminary pilot survey on head lice, pediculosis in Sharkia Governorate and treatment of lice with natural plant extracts. J Egyptian Soc Parasitol 2002; 32:725-736.
    11) Elliot CG, Colby TV, & Kelly TM: Charcoal lung. Bronchiolitis obliterans after aspiration of activated charcoal. Chest 1989; 96:672-674.
    12) FDA: Poison treatment drug product for over-the-counter human use; tentative final monograph. FDA: Fed Register 1985; 50:2244-2262.
    13) Golej J, Boigner H, Burda G, et al: Severe respiratory failure following charcoal application in a toddler. Resuscitation 2001; 49:315-318.
    14) Graff GR, Stark J, & Berkenbosch JW: Chronic lung disease after activated charcoal aspiration. Pediatrics 2002; 109:959-961.
    15) Harris CR & Filandrinos D: Accidental administration of activated charcoal into the lung: aspiration by proxy. Ann Emerg Med 1993; 22:1470-1473.
    16) Jellin JM, Gregory P, & Batz F: Pharmacist's letter/Prescriber's Letter Natural Medicines Comprehensive Database, 3rd ed, Therapeutic Research Faculty, Stockton, CA, 2000.
    17) Kandil HH, Al-Ghanem MM, & Sarwat MA: Henna (Lawsonia inermis Linn) inducing haemolysis among G6PD-deficient newborns. A new clinical observation. Ann Tropical Paediatrics 1996; 16:287-291.
    18) Katar S, Devecioglu C, Ozbek MN, et al: Henna causes life-threatening hyperbilirubinaemia in glucose-6-phosphate dehydrogenase deficiency. Clin Exp Dermatol 2007; 32(2):235-236.
    19) Kok AN, Ertekin MV, Ertekin V, et al: Henna (Lawsonia inermis Linn.) induced haemolytic anaemia in siblings. Int J Clin Pract 2004; 58(5):530-532.
    20) Kok AN, Ertekin V, Bilge Y, et al: An unusual cause of suicide: henna (Lawsonia inermis Linn.). J Emerg Med 2005; 29(3):343-344.
    21) Lestringant GG, Bener A, & Frossard PM: Cutaneous reactions to henna and associated additives (letter). Br J Dermatol 1999; 141:598-600.
    22) Majoie IML & Bruynzeel DP: Case Report: occupational immediate-type hypersensitivity to henna in a hairdresser. Am J Contact Dermat 1996; 7(1):38-40.
    23) Nawaf AM, Joshi A, & Nour-Eldin O: Acute allergic contact dermatitis due to para-phenylenediamine after temporary henna painting. J Dermatol 2003; 30:797-800.
    24) None Listed: Position paper: cathartics. J Toxicol Clin Toxicol 2004; 42(3):243-253.
    25) Oztass MO, Onder M, & Oztab P: Contact allergy to henna (letter). J Eur Acad Dermatol Venerol 2001; 15:91-92.
    26) Pollack MM, Dunbar BS, & Holbrook PR: Aspiration of activated charcoal and gastric contents. Ann Emerg Med 1981; 10:528-529.
    27) Product Information: Henna, Lawsonia inermis. PDR. For Herbal Medicines. Medical Economics Company, Montvale, NJ, 2003.
    28) Qurashi HE, Qumqumji AA, & Zacharia Y: Acute renal failure and intravascular hemolysis following henna ingestion. Saudi J Kidney Dis Transpl 2013; 24(3):553-556.
    29) Rau NR, Nagaraj MV, Prakash PS, et al: Fatal pulmonary aspiration of oral activated charcoal. Br Med J 1988; 297:918-919.
    30) Raupp P, Hassan JA, & Varughese M: Henna causes life threatening haemolysis in glucose-6-phosphate dehydrogenase deficiency. Arch Dis Child 2001; 85:411-412.
    31) Rubegni P, Fimiani M, & De Aloe G: Lichenoid reaction to temporary tattoo. Contact Derm 2000; 42:117-118.
    32) Scibilia J, Galdi E, & Biscaldi G: Occupational asthma caused by black henna. Allergy 1997; 52(2):231-232.
    33) Wolf R, Wolf D, Matz H, et al: Cutaneous reactions to temporary tattoos. Dermatol Online J 2003; 9:3.
    34) Zinkham WH & Oski FA: Henna: a potential cause of oxidative hemolysis and neonatal hyperbilirubinemia. Pediatrics 1996; 97:707-709.